SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 84 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 1.11 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $45,264,321 | +22.6% | 2,143,197 | +47.7% | 1.66% | +6.2% |
| Q4 2022 | $36,932,964 | -14.5% | 1,451,197 | -19.3% | 1.56% | -12.7% |
| Q3 2022 | $43,208,000 | -4.7% | 1,798,085 | -23.7% | 1.78% | -18.5% |
| Q2 2022 | $45,347,000 | +9.0% | 2,356,934 | -1.6% | 2.19% | +31.5% |
| Q1 2022 | $41,620,000 | -9.4% | 2,394,714 | +14.0% | 1.66% | -0.2% |
| Q4 2021 | $45,963,000 | -3.3% | 2,099,714 | -15.6% | 1.67% | -10.0% |
| Q3 2021 | $47,516,000 | +11.3% | 2,486,429 | 0.0% | 1.85% | +15.9% |
| Q2 2021 | $42,692,000 | +1067.7% | 2,486,429 | +1420.5% | 1.60% | +1067.9% |
| Q1 2021 | $3,656,000 | -81.3% | 163,524 | -81.4% | 0.14% | -82.2% |
| Q4 2020 | $19,538,000 | -46.4% | 878,524 | -64.4% | 0.77% | -61.3% |
| Q3 2020 | $36,467,000 | -0.4% | 2,470,678 | 0.0% | 1.99% | -12.0% |
| Q2 2020 | $36,615,000 | +56.0% | 2,470,678 | +15.5% | 2.26% | +3.2% |
| Q1 2020 | $23,473,000 | +51.5% | 2,139,784 | +21.2% | 2.19% | +86.2% |
| Q4 2019 | $15,495,000 | +17.5% | 1,764,784 | 0.0% | 1.18% | -15.2% |
| Q3 2019 | $13,183,000 | -19.8% | 1,764,784 | 0.0% | 1.38% | -22.8% |
| Q2 2019 | $16,430,000 | +57.5% | 1,764,784 | -11.2% | 1.79% | +53.6% |
| Q1 2019 | $10,435,000 | +18.0% | 1,987,669 | 0.0% | 1.17% | +1.0% |
| Q4 2018 | $8,845,000 | -11.3% | 1,987,669 | +61.1% | 1.16% | +32.0% |
| Q3 2018 | $9,968,000 | +15.1% | 1,233,618 | 0.0% | 0.88% | +3.7% |
| Q2 2018 | $8,660,000 | -81.2% | 1,233,618 | -61.9% | 0.84% | -81.9% |
| Q1 2018 | $46,014,000 | +62.4% | 3,233,618 | 0.0% | 4.66% | +36.6% |
| Q4 2017 | $28,326,000 | – | 3,233,618 | – | 3.42% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |